Skip to main content
Fig. 2 | Journal of Ovarian Research

Fig. 2

From: Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis

Fig. 2

LncRNA NKILA negatively associates with cisplatin resistance and c-Myb expression. qRT-PCR was used to assess NKILA levels in parental and cisplatin resistant ES2 (A) and A2780 (B) cells with an additional silencing of c-Myb in resistant cells (ES2C-si / A2780C-si). The presented results are representative of at least 3 different repeats with triplicate samples in each repeat.

Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us